APX005M and Doxorubicin in Advanced Sarcoma

Soft Tissue Sarcoma Clinical Trial

Official title:

A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03719430
• Other study ID #: AAAS0095
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 20, 2019
• Est. completion date: December 31, 2025

Study information

• Verified date: March 2024
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.

Description:

Doxorubicin, a chemotherapy, is currently considered standard-of-care treatment for most advanced soft tissue sarcomas. This study will assess the safety and efficacy of combining APX005M, a novel immunomodulatory drug, together with standard of care doxorubicin, for the treatment of patients with advanced soft tissue sarcoma. APX005M is an agonistic monoclonal antibody targeting the CD40 receptor and may have favorable effects on certain types of immune cells in sarcoma tumors, particularly macrophages.

The primary objective is to determine the objective response rate. Secondary objectives include further evaluation of safety and efficacy. A subset of patients will undergo tumor biopsies at baseline and while on study treatment to help understand how the drug combination works and to evaluate how the composition of immune cells in the tumor changes after the treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 27
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Histologically confirmed advanced soft tissue sarcoma for which doxorubicin treatment is considered appropriate. Patients with well-differentiated liposarcoma who have histologic evidence of a dedifferentiated component are eligible. Kaposi sarcoma and gastrointestinal stromal tumor (GIST) are not eligible. Protocol Amendment 4 restricts further enrollment to participants with the following sarcoma subtypes. A total of 10 patients will be enrolled with each of the following sarcoma subtypes for the entire study, inclusive of patients enrolled prior to Amendment 4:

• Dedifferentiated liposarcoma

• Leiomyosarcoma

• Myxofibrosarcoma/undifferentiated pleomorphic sarcoma

2. Disease must be locally advanced and unresectable or metastatic (that is, considered not amenable to curative surgery or radiation).

3. Patients must have measurable disease by RECIST criteria version 1.1.

4. Patients must demonstrate an ECOG performance status of 0 or 1 and be considered an appropriate candidate for anthracycline chemotherapy. There is no limit on prior lines of systemic therapy received. Treatment naïve patients may be enrolled.

5. Acceptable laboratory parameters:

• Absolute neutrophil count (ANC) = 1,500/mm3

• Hemoglobin = 9 g/dL

• Platelets = 100,000/mm3

• Creatinine = 1.5 times upper limit of normal OR Calculated creatinine clearance > 45 mL/min

• Total bilirubin = upper limit of normal

• AST/ALT = 1.5 times upper limit of normal

6. Patients must have normal left ventricular systolic function, as demonstrated by a transthoracic echocardiogram or MUGA scan at screening, showing a normal left ventricular ejection fraction as defined by the laboratory performing the test.

7. Women of child-bearing potential and all men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of study participation, and for 4 months after completion of study drug administration.

8. Ability to understand and willingness to sign a written informed consent document.

9. After the safety lead-in phase is complete, the next consecutive 10 patients enrolled on the study must have a site of tumor tissue which is amenable to image-guided biopsy by interventional radiology with at most minimal risk to the patient. These 10 patients will be required to undergo tumor biopsy at screening and while on-treatment.

Exclusion Criteria

1. Patients must not have received treatment with any chemotherapy, immunotherapy, radiotherapy or an investigational agent for malignancy within the 21 days preceding registration. Patients may not have received treatment with a small molecule targeted anti-cancer agent within 14 days preceding study registration, provided this represents at least 7 half-lives for that agent. Furthermore, toxic effects from any prior therapy (except alopecia) must have resolved to = grade 1 by NCI CTCAE v 5.0 or to the patient's baseline by registration.

2. Patients may not be receiving any other investigational agent for any purpose.

3. Patients may not have received prior treatment with:

• any anthracycline chemotherapy

• CD40 agonist

4. Patients may not have received prior radiotherapy of the mediastinal or pericardial area or whole pelvis radiation.

5. Patients may not have active, known or suspected autoimmune disease with the exceptions of well-controlled: asthma or allergic rhinitis, vitiligo, type 1 diabetes mellitus, psoriasis, or hypothyroidism.

6. Patients may not be receiving chronic systemic steroid therapy in excess of physiologic/ replacement doses (prednisone = 10 mg/day is acceptable), or on any other form of immunosuppressive medication for 14 days prior to registration.

7. Patients with symptomatic brain metastases may not be enrolled. Those subjects with untreated brain metastases = 1 cm who are asymptomatic and for whom there are no plans for surgery, radiation or corticosteroid use may be considered eligible at the discretion of the principal investigator. Subjects with brain metastases that have been treated and are stable for at least 30 days are eligible if asymptomatic and not receiving corticosteroids. Screening for brain metastases is not required and should not be routinely pursued given their uncommon incidence in sarcoma.

8. Patients may not have:

• uncontrolled intercurrent illness including, but not limited to congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmias, uncontrolled diabetes mellitus or uncontrolled psychiatric illness that would limit compliance with study requirements in the opinion of the investigator.

• unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction within 6 months of registration.

• any thromboembolic event within 1 month prior to registration

• any active coagulopathy

• any clinically serious, active infection requiring treatment with antibiotics within 14 days prior to registration

• major surgery within 28 days of registration.

9. Patients may not have history of another primary cancer, with the exception of:

• curatively treated non-melanomatous skin cancer,

• curatively treated cervical carcinoma in-situ,

• other primary cancers treated with curative intent, no known active disease and no treatment administered within 2 years prior to registration.

• other cancers considered indolent and for which no treatment is anticipated, in the opinion of the principal investigator

10. Patients may not be pregnant or nursing.

11. Patients may not have known HIV or hepatitis A, B or C infection; however, screening tests for these infections are not required.

Related Conditions & MeSH terms

• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• Doxorubicin
Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
• APX005M
APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)

Locations

Country	Name	City	State
United States	City of Hope	Duarte	California
United States	Columbia University Irving Medical Center/NYP	New York	New York
United States	Washington University School of Medicine - Siteman Cancer Center	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Alexander Z. Wei, MD	Apexigen America, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in Immune Cell Infiltrates in Baseline and On-Study Biopsies	Correlative/Exploratory Study	18 months
Other	Expression of CD40 in Baseline Study Biopsies	Correlative/Exploratory Study	18 months
Primary	Objective Response Rate	The percentage of patients achieving a partial or complete response as measured by imaging assessments from study treatment	6 months
Secondary	Recommended Dose Combination for APX005M and Doxorubicin and Combination Treatment	A safety-lead in phase will be conducted during which a small number of patients will be treated and monitored closely for certain side effects. If these side effects are seen, the dose of doxorubicin will be adjusted and the study treatment reassessed among another small number of patients. The purpose of the safety lead-in phase is to establish a safe and tolerable dose combination ("the recommended dose") which will be used during the remainder of the study.	6 months
Secondary	Evaluation of Side Effects from APXO05M and Doxorubicin Treatment	Patients on the study will be assessed at regular intervals during clinical visits and through laboratory testing to monitor side effects from the study treatment.	18 months
Secondary	Progression Free Survival	The mean time to either disease progression or death, whichever comes first, for patients on the study	18 months
Secondary	Objective Response Rate (ORR)	Objective response rate in patients with dedifferentiated liposarcoma, leiomyosarcoma, and myxofibrosarcoma/undifferentiated pleomorphic sarcoma. The confirmed ORR per RECIST version 1.1. criteria will be evaluated in the group of patients with these 3 sarcoma subtypes and within each of these subtypes.	1 year